-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYT-200 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYT-200 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYT-200 in Relapsed Acute Myeloid Leukemia Drug Details: LYT-200...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab in Malignant Mesothelioma Drug Details: Avelumab (MSB-0010718C, Bavencio) is a...
-
Product Insights
Carcinoid Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Carcinoid Tumor - Drugs In Development, 2023’, provides an overview of the Carcinoid Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Carcinoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gallbladder Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Gallbladder Cancer - Drugs In Development, 2023’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Tumors - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QBS-10072S in Oral Cavity (Mouth) Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. QBS-10072S in Oral Cavity (Mouth) Cancer Drug Details: QBS-10072S is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-001 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-001 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-001 in Breast Cancer Drug Details: AB-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-001 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-001 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-001 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-001 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-001 in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-001 in Colon Cancer Drug Details: AB-001 is under development for the...